share_log

Medtronic | 8-K: Current report

Medtronic | 8-K: Current report

美敦力 | 8-K：重大事件
美股SEC公告 ·  2024/06/03 06:55

Moomoo AI 已提取核心訊息

Medtronic Inc., a subsidiary of Medtronic plc, issued €3 billion in senior notes across four tranches on June 3, 2024. The offering includes €850M of 3.650% notes due 2029, €850M of 3.875% notes due 2036, €600M of 4.150% notes due 2043, and €700M of 4.150% notes due 2053. The company expects to receive net proceeds of approximately €2.97B after deducting underwriting discounts and expenses.The notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, ranking equally with other unsecured senior indebtedness. The proceeds will be used for general corporate purposes, including repayment of outstanding commercial paper and other debt. The notes will be listed on the New York Stock Exchange.Each series of notes includes redemption provisions allowing early redemption at specified prices before their respective Par Call Dates. After the Par Call Dates, the notes can be redeemed at 100% of principal plus accrued interest. The financial impact of this offering was incorporated into Medtronic's fiscal year 2025 adjusted EPS guidance announced on May 23, 2024.
Medtronic Inc., a subsidiary of Medtronic plc, issued €3 billion in senior notes across four tranches on June 3, 2024. The offering includes €850M of 3.650% notes due 2029, €850M of 3.875% notes due 2036, €600M of 4.150% notes due 2043, and €700M of 4.150% notes due 2053. The company expects to receive net proceeds of approximately €2.97B after deducting underwriting discounts and expenses.The notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, ranking equally with other unsecured senior indebtedness. The proceeds will be used for general corporate purposes, including repayment of outstanding commercial paper and other debt. The notes will be listed on the New York Stock Exchange.Each series of notes includes redemption provisions allowing early redemption at specified prices before their respective Par Call Dates. After the Par Call Dates, the notes can be redeemed at 100% of principal plus accrued interest. The financial impact of this offering was incorporated into Medtronic's fiscal year 2025 adjusted EPS guidance announced on May 23, 2024.
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    重磅財報來襲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 🎙️討論： 1. Deepseek引發了中國資產的一輪上漲。你對未來市場的看法如何？ 2. 包括 $阿里巴巴 (BABA.US)$ 和 $嗶哩嗶哩 (BILI.US)$ 在 展开
    阿里巴巴(臨時代碼)2024財年第四季度業績電話會